Resources

Source of Lenacapavir for PrEP Supply to Early Adopter Countries

The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.

Source of Lenacapavir for PrEP Supply in Africa

Lenacapavir for PrEP has now reached seventeen countries in Africa. This map offers more detail on the LEN rollout.

Advancing Access to LEN for PrEP in Kenya, Malawi, and Uganda

Reflections and lessons learned from partners and Ministries of Health on projects to support locally tailored, sustainable, choice-centered rollout of injectable Lenacapavir (LEN) Since its launch in December 2025, LEN for PrEP has been...

New Congress, who dis? Understanding how power has shifted after the election

How will power shift with the new Congress? The Positive Women’s Network-USA hosts a webinar that digs into how political power will shift after the election and what the results mean for people living with HIV in the US and abroad. Panelists:

Moving a Product to the Real World

To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.

Going Faster with LEN Generics

The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.

Now What with Injectable LEN for PrEP

Since results of the PURPOSE efficacy trials were announced in 2024, injectable lenacapavir for PrEP (LEN) has generated enormous excitement and opportunity – and frustration. By the end of 2024, Gilead Sciences provided six voluntary licenses to generic manufacturers and submitted multiple regulatory filings, and the Global Fund and PEPFAR committed to an ambition to reach two million people over three years, pending regulatory approvals and WHO guidelines. It seemed like bold ambition – and it was, compared to the previous launches of oral PrEP, vaginal ring and CAB.

But this ambition was always defined as a floor, not a ceiling. In April 2026, the collaboration increased the goal to reach three million people over three years with LEN for PrEP. In July 2025, AVAC published a first edition of Now What with Injectable LEN for PrEP, outlining priorities to ensure introduction moved swiftly. Now, in this update, AVAC is calling for a new minimum floor: reach three million in two years (2026-2027). No less and no slower, with a push for more and faster.

HIV Prevention Product Overview

The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.

Preparing for LEN

In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.

Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.